Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04519411
  4. Details
NCT04519411 Clinical Trial

Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure

COVID 19 Clinical Trial

Official title:
Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT04519411
Other study ID # 20-003743
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date May 21, 2020
Est. completion date December 2022

Study information
Verified date February 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to gather information to help doctors understand how Covid-19 affects the lungs in children.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group N/A to 17 Years
Eligibility Inclusion Criteria: - Patients 0-17 years of age, 10 kg or greater, with suspected or confirmed Covid-19 respiratory failure requiring endotracheal intubation and mechanical ventilation admitted to Mayo Clinic Hospital, St. Mary's Campus Pediatric Intensive Care Unit. Exclusion Criteria: - Patients <10 kg - Patients with pre-existing chronic mechanical ventilation (chronic respiratory failure) - Patients with known esophageal disease (strictures, known esophageal anatomic abnormalities) - Patients with severe coagulopathy (for which placement of esophageal balloon or other gastric tube via nose or mouth is contraindicated) - Patients who are pregnant (as determined by standard pregnancy testing criteria for Pediatric ICU admission).

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Transpulmonary pressure measurements
Transpulmonary pressure measurements

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Mayo Clinic

Outcome
Type Measure Description Time frame Safety issue
Primary Transpulmonary pressure Numerical data Through study complication, usually 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT04333732 - CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION Phase 3
Completed NCT04357457 - Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia Phase 3
Terminated NCT04435795 - Inhaled Ciclesonide for Outpatients With COVID19 Phase 2/Phase 3
Completed NCT04357444 - Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 Phase 2
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT05052320 - Audiological Assessment of Recovered Covid 19 Subjects.
Withdrawn NCT04426344 - Core Warming of COVID-19 Patients N/A
Recruiting NCT05595031 - Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Terminated NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Completed NCT04445337 - Stellate Ganglion Blockade in COVID-19 Positive Patients N/A
Active, not recruiting NCT04374487 - Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications Phase 2
Completed NCT04403243 - COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19 Phase 2
Completed NCT04375644 - Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
Completed NCT04394078 - Impact of COVID-19 Pandemic on Depression and Quality of Life
Recruiting NCT04407923 - Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
Completed NCT04426305 - Community Health Workers Against COVID19 N/A
Recruiting NCT04492514 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation Phase 2
Completed NCT04399980 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Phase 2
Completed NCT04403828 - Impact of COVID-19 on Personal Protection Among Dentist in Egypt

External Links